Cargando…

p38 MAPK signaling in chronic obstructive pulmonary disease pathogenesis and inhibitor therapeutics

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar remodeling. Although the abnormalities are primarily prompted by chronic exposure to inhaled irritants, maladjusted and self-reinforcing i...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmadi, Ali, Ahrari, Sajjad, Salimian, Jafar, Salehi, Zahra, Karimi, Mehrdad, Emamvirdizadeh, Alireza, Jamalkandi, Sadegh Azimzadeh, Ghanei, Mostafa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623820/
https://www.ncbi.nlm.nih.gov/pubmed/37919729
http://dx.doi.org/10.1186/s12964-023-01337-4
_version_ 1785130817597472768
author Ahmadi, Ali
Ahrari, Sajjad
Salimian, Jafar
Salehi, Zahra
Karimi, Mehrdad
Emamvirdizadeh, Alireza
Jamalkandi, Sadegh Azimzadeh
Ghanei, Mostafa
author_facet Ahmadi, Ali
Ahrari, Sajjad
Salimian, Jafar
Salehi, Zahra
Karimi, Mehrdad
Emamvirdizadeh, Alireza
Jamalkandi, Sadegh Azimzadeh
Ghanei, Mostafa
author_sort Ahmadi, Ali
collection PubMed
description BACKGROUND: Chronic obstructive pulmonary disease (COPD) is characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar remodeling. Although the abnormalities are primarily prompted by chronic exposure to inhaled irritants, maladjusted and self-reinforcing immune responses are significant contributors to the development and progression of the disease. The p38 isoforms are regarded as pivotal hub proteins that regulate immune and inflammatory responses in both healthy and disease states. As a result, their inhibition has been the subject of numerous recent studies exploring their therapeutic potential in COPD. MAIN BODY: We performed a systematic search based on the PRISMA guidelines to find relevant studies about P38 signaling in COPD patients. We searched the PubMed and Google Scholar databases and used “P38” AND “COPD” Mesh Terms. We applied the following inclusion criteria: (1) human, animal, ex vivo and in vitro studies; (2) original research articles; (3) published in English; and (4) focused on P38 signaling in COPD pathogenesis, progression, or treatment. We screened the titles and abstracts of the retrieved studies and assessed the full texts of the eligible studies for quality and relevance. We extracted the following data from each study: authors, year, country, sample size, study design, cell type, intervention, outcome, and main findings. We classified the studies according to the role of different cells and treatments in P38 signaling in COPD. CONCLUSION: While targeting p38 MAPK has demonstrated some therapeutic potential in COPD, its efficacy is limited. Nevertheless, combining p38 MAPK inhibitors with other anti-inflammatory steroids appears to be a promising treatment choice. Clinical trials testing various p38 MAPK inhibitors have produced mixed results, with some showing improvement in lung function and reduction in exacerbations in COPD patients. Despite these mixed results, research on p38 MAPK inhibitors is still a major area of study to develop new and more effective therapies for COPD. As our understanding of COPD evolves, we may gain a better understanding of how to utilize p38 MAPK inhibitors to treat this disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-023-01337-4.
format Online
Article
Text
id pubmed-10623820
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106238202023-11-04 p38 MAPK signaling in chronic obstructive pulmonary disease pathogenesis and inhibitor therapeutics Ahmadi, Ali Ahrari, Sajjad Salimian, Jafar Salehi, Zahra Karimi, Mehrdad Emamvirdizadeh, Alireza Jamalkandi, Sadegh Azimzadeh Ghanei, Mostafa Cell Commun Signal Review BACKGROUND: Chronic obstructive pulmonary disease (COPD) is characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar remodeling. Although the abnormalities are primarily prompted by chronic exposure to inhaled irritants, maladjusted and self-reinforcing immune responses are significant contributors to the development and progression of the disease. The p38 isoforms are regarded as pivotal hub proteins that regulate immune and inflammatory responses in both healthy and disease states. As a result, their inhibition has been the subject of numerous recent studies exploring their therapeutic potential in COPD. MAIN BODY: We performed a systematic search based on the PRISMA guidelines to find relevant studies about P38 signaling in COPD patients. We searched the PubMed and Google Scholar databases and used “P38” AND “COPD” Mesh Terms. We applied the following inclusion criteria: (1) human, animal, ex vivo and in vitro studies; (2) original research articles; (3) published in English; and (4) focused on P38 signaling in COPD pathogenesis, progression, or treatment. We screened the titles and abstracts of the retrieved studies and assessed the full texts of the eligible studies for quality and relevance. We extracted the following data from each study: authors, year, country, sample size, study design, cell type, intervention, outcome, and main findings. We classified the studies according to the role of different cells and treatments in P38 signaling in COPD. CONCLUSION: While targeting p38 MAPK has demonstrated some therapeutic potential in COPD, its efficacy is limited. Nevertheless, combining p38 MAPK inhibitors with other anti-inflammatory steroids appears to be a promising treatment choice. Clinical trials testing various p38 MAPK inhibitors have produced mixed results, with some showing improvement in lung function and reduction in exacerbations in COPD patients. Despite these mixed results, research on p38 MAPK inhibitors is still a major area of study to develop new and more effective therapies for COPD. As our understanding of COPD evolves, we may gain a better understanding of how to utilize p38 MAPK inhibitors to treat this disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-023-01337-4. BioMed Central 2023-11-02 /pmc/articles/PMC10623820/ /pubmed/37919729 http://dx.doi.org/10.1186/s12964-023-01337-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Ahmadi, Ali
Ahrari, Sajjad
Salimian, Jafar
Salehi, Zahra
Karimi, Mehrdad
Emamvirdizadeh, Alireza
Jamalkandi, Sadegh Azimzadeh
Ghanei, Mostafa
p38 MAPK signaling in chronic obstructive pulmonary disease pathogenesis and inhibitor therapeutics
title p38 MAPK signaling in chronic obstructive pulmonary disease pathogenesis and inhibitor therapeutics
title_full p38 MAPK signaling in chronic obstructive pulmonary disease pathogenesis and inhibitor therapeutics
title_fullStr p38 MAPK signaling in chronic obstructive pulmonary disease pathogenesis and inhibitor therapeutics
title_full_unstemmed p38 MAPK signaling in chronic obstructive pulmonary disease pathogenesis and inhibitor therapeutics
title_short p38 MAPK signaling in chronic obstructive pulmonary disease pathogenesis and inhibitor therapeutics
title_sort p38 mapk signaling in chronic obstructive pulmonary disease pathogenesis and inhibitor therapeutics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623820/
https://www.ncbi.nlm.nih.gov/pubmed/37919729
http://dx.doi.org/10.1186/s12964-023-01337-4
work_keys_str_mv AT ahmadiali p38mapksignalinginchronicobstructivepulmonarydiseasepathogenesisandinhibitortherapeutics
AT ahrarisajjad p38mapksignalinginchronicobstructivepulmonarydiseasepathogenesisandinhibitortherapeutics
AT salimianjafar p38mapksignalinginchronicobstructivepulmonarydiseasepathogenesisandinhibitortherapeutics
AT salehizahra p38mapksignalinginchronicobstructivepulmonarydiseasepathogenesisandinhibitortherapeutics
AT karimimehrdad p38mapksignalinginchronicobstructivepulmonarydiseasepathogenesisandinhibitortherapeutics
AT emamvirdizadehalireza p38mapksignalinginchronicobstructivepulmonarydiseasepathogenesisandinhibitortherapeutics
AT jamalkandisadeghazimzadeh p38mapksignalinginchronicobstructivepulmonarydiseasepathogenesisandinhibitortherapeutics
AT ghaneimostafa p38mapksignalinginchronicobstructivepulmonarydiseasepathogenesisandinhibitortherapeutics